If you ask pharma marketing teams why MLR review takes so long, you'll hear the same answers: too many reviewers, too many comments, too much back-and-forth. These are real problems. But they're symptoms of a deeper issue that almost nobody addresses directly: the version problem.
Medical, Legal, and Regulatory reviewers regularly end up looking at different iterations of the same document. Marketing sends a revised file to Legal on Tuesday. Regulatory receives an earlier version on Monday. Medical has been annotating something from last week. Everyone does their job. The review still fails — not because anyone was careless, but because there was never a single, controlled source of truth.
Why Version Confusion Is the Real Bottleneck
MLR review cycles in pharma can stretch to two months or longer. Industry data suggests that AI-assisted workflows can reduce review time by two to three times — but most companies aren't capturing that benefit because the process architecture hasn't changed. Email-based routing, spreadsheet tracking, and informal version naming continue to dominate even at large organizations.
The result is predictable. Teams lose track of approved versions and risk publishing outdated content. Reviewers comment on material that has already been revised. Sign-offs are given against documents that don't match what gets submitted. According to MarketBeam's 2026 analysis of pharma marketing compliance, email-based routing and spreadsheet tracking are among the most cited causes of missed approvals and version confusion — not reviewer bandwidth.
The Process Problem, Not the People Problem
This distinction matters. When MLR delays are framed as a resourcing or culture issue, the default response is to add more reviewers or run training sessions. Neither fixes the underlying architecture. When MLR is understood as a version control problem, the intervention is entirely different: a controlled document environment where every reviewer sees the same version, changes are tracked automatically, and approvals are tied to a specific, verifiable file state.
Indegene estimates that 80% of review and approval responsibilities can be handled with appropriate automation — but only where the process is designed to support it. The remaining 20% — complex or high-risk content — still needs the human review it deserves. The point isn't to remove judgement from MLR. It's to stop wasting reviewer time on version reconciliation.
The Better Option
Pharma companies that have re-engineered their MLR content operations report campaign approval timelines compressing from three months to three weeks, MLR teams processing fewer repetitive reviews, and marketing teams spending more time on planning and less time chasing annotations.
None of that requires adding headcount to the review process. It requires treating the document itself — and control over its versions — as the foundation of the workflow, rather than an afterthought.
The MLR bottleneck is solvable. But not until organizations stop diagnosing it as a people problem and start treating it as a process architecture problem.
